Advanced glycation end products-mediated hypertrophy is negatively regulated by tetrahydrobiopterin in renal tubular cells

Molecular and Cellular Endocrinology

Volumn 355, Issue 1, 2012, Pages 71-77

  Liao, Yi Chen ^a,b   Lee, Ying Ho ^b,c   Chuang, Lea Yea ^d   Guh, Jinn Yuh ^d   Shi, Ming Der ^c   Huang, Jau Shyang ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^c Yongkang Veterans Hospital   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; GTP cyclohydrolase I; Hypertrophy; Inducible nitric oxide synthase; Nitric oxide; Tetrahydrobiopterin

Indexed keywords

2,4 DIAMINO 6 HYDROXYPYRIMIDINE; ADVANCED GLYCATION END PRODUCT; ALPHA SMOOTH MUSCLE ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIHYDROBIOPTERIN; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NITRIC OXIDE; SEPIAPTERIN; STAT1 PROTEIN; STAT3 PROTEIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; KIDNEY HYPERTROPHY; KIDNEY TUBULE CELL; KIDNEY TUBULE DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; BIOPTERIN; CELL ENLARGEMENT; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GTP CYCLOHYDROLASE; HUMANS; JANUS KINASE 2; KIDNEY TUBULES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PTERINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUGAR ACIDS;

EID: 84862799001     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.01.018     Document Type: Article

References (40)

1. Arellano-Mendoza M.G., Vargas-Robles H., Del Valle-Mondragon L., Rios A., Escalante B. Prevention of renal injury and endothelial dysfunction by chronic l-arginine and antioxidant treatment. Ren. Fail. 2011, 33:47-53.
2. Berbée M., Fu Q., Kumar K.S., Hauer-Jensen M. Novel strategies to ameliorate radiation injury: a possible role for tetrahydrobiopterin. Curr. Drug Targets 2010, 11:1366-1374.
3. Bohlender J.M., Franke S., Stein G., Wolf G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 2005, 289:645-659.
4. Cerra M.C., Pellegrino D. Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr. Med. Chem. 2007, 14:585-599.
5. Coughlan M.T., Mibus A.L., Forbes J.M. Oxidative stress and advanced glycation in diabetic nephropathy. Ann. N. Y. Acad. Sci. 2008, 1126:190-193.
6. Crabtree M.J., Channon K.M. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 2011, 25:81-88.
7. Da Ros R., Assaloni R., Ceriello A. Antioxidant therapy in diabetic complications: what is new?. Curr. Vasc. Pharmacol. 2004, 2:335-341.
8. Evans R.G., Fitzgerald S.M. Nitric oxide and superoxide in the renal medulla: a delicate balancing act. Curr. Opin. Nephrol. Hypertens. 2005, 14:9-15.
9. Fidan I., Yüksel S., Ymir T., Irkeç C., Aksakal F.N. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J. Neuroimmunol. 2006, 171:184-188.
10. Forbes J.M., Fukami K., Cooper M.E. Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 2007, 115:69-84.
11. Forbes J.M., Coughlan M.T., Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
12. Garvin J.L., Herrera M., Ortiz P.A. Regulation of renal NaCl transport by nitric oxide, endothelin, and ATP: clinical implications. Annu. Rev. Physiol. 2011, 73:359-376.
13. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
14. Huang J.S., Chuang L.Y., Guh J.Y., Chen C.J., Yang Y.L., Chiang T.A., Hung M.Y., Liao T.N. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced glycation end-product-induced proliferation in renal fibroblasts. J. Am. Soc. Nephrol. 2005, 16:2318-2329.
15. Huang J.S., Chuang L.Y., Guh J.Y., Huang Y.J. Effects of nitric oxide and antioxidants on advanced glycation end products-induced hypertrophic growth in human renal tubular cells. Toxicol. Sci. 2009, 111:109-119.
16. Huisman A., Vos I., van Faassen E.E., Joles J.A., Gröne H.J., Martasek P., van Zonneveld A.J., Vanin A.F., Rabelink T.J. Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase. FASEB J. 2002, 16:1135-1147.
17. Kang D.H., Nakagawa T., Feng L., Johnson R.J. Nitric oxide modulates vascular disease in the remnant kidney model. Am. J. Pathol. 2002, 161:239-248.
18. Lee H.B., Yu M.R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:s241-245.
19. Legrand M., Kandil A., Payen D., Ince C. Effects of sepiapterin infusion on renal oxygenation and early acute renal injury after suprarenal aortic clamping in rats. J. Cardiovasc. Pharmacol. 2011, 58:192-198.
20. Levine D.Z. Hyperfiltration, nitric oxide, and diabetic nephropathy. Curr. Hypertens. Rep. 2006, 8:153-157.
21. 2+ signaling of cultured human mesangial cells. J. Am. Soc. Nephrol. 1999, 10:1478-1486.
22. Moens A.L., Kass D.A. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J. Cardiovasc. Pharmacol. 2007, 50:238-246.
23. Niedowicz D.M., Daleke D.L. The role of oxidative stress in diabetic complications. Cell. Biochem. Biophys. 2005, 43:289-330.
24. Noh H., Ha H., Yu M.R., Kang S.W., Choi K.H., Han D.S., Lee H.Y. High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron 2002, 90:78-85.
25. Okumura M., Masada M., Yoshida Y., Shintaku H., Hosoi M., Okada N., Konishi Y., Morikawa T., Miura K., Imanishi M. Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney Int. 2006, 70:471-476.
26. Onozato M.L., Tojo A., Goto A., Fujita T., Wilcox C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002, 61:186-194.
27. Pennathur S., Heinecke J.W. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid. Redox. Signal. 2007, 9:955-969.
28. Prabhakar S.S. Tetrahydrobiopterin reverses the inhibition of nitric oxide by high glucose in cultured murine mesangial cells. Am. J. Physiol. Renal. Physiol. 2001, 281:179-188.
29. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998, 31:189-193.
30. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M. TAGE (toxic AGE) theory in diabetic complications. Curr. Mol. Med. 2006, 6:351-358.
31. Satoh M., Fujimoto S., Arakawa S., Yada T., Namikoshi T., Haruna Y., Horike H., Sasaki T., Kashihara N. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol. Dial. Transplant. 2008, 23:3806-3813.
32. Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr. Drug Metab. 2002, 3:123-131.
33. Singh D.K., Winocour P., Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat. Rev. Endocrinol. 2011, 7:176-184.
34. Studer R.K., DeRubertis F.R., Craven P.A. Nitric oxide suppresses increases in mesangial cell protein kinase C, transforming growth factor beta, and fibronectin synthesis induced by thromboxane. J. Am. Soc. Nephrol. 1996, 7:999-1005.
35. Sucher R., Gehwolf P., Oberhuber R., Hermann M., Margreiter C., Werner E.R., Obrist P., Schneeberger S., Ollinger R., Margreiter R., Brandacher G. Tetrahydrobiopterin protects the kidney from ischemia-reperfusion injury. Kidney Int. 2010, 77:681-689.
36. Tan A.L., Forbes J.M., Cooper M.E. AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 2007, 27:130-143.
37. Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am. J. Kidney Dis. 2010, 55:928-940.
38. + when the Griess reaction is used to assay for nitrite. Anal. Biochem. 1995, 224:502-508.
39. Yoshida M., Nakanishi N., Wang X., Hattori Y. Exogenous biopterins requirement for iNOS function in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2003, 42:197-203.
40. Zheng L., Sinniah R., Hsu S.I. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum. Pathol. 2006, 37:637-647.